Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
danirixin
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Inhalation
01
Overview
Danirixin is a selective, competitive, and reversible antagonist of the C-X-C chemokine receptor type 2 (CXCR2), also known as the interleukin 8B receptor. It is a small molecule developed primarily as an anti-inflammatory agent. By blocking CXCR2, danirixin inhibits neutrophil chemotaxis and activation in response to inflammatory signals such as CXCL8 (IL-8), thereby reducing neutrophil-driven inflammation. The drug has been investigated for use in diseases characterized by excessive neutrophilic inflammation, including chronic obstructive pulmonary disease (COPD), influenza virus infections, and respiratory syncytial virus infections. Clinical trials have reached phase II for influenza virus infections but development for COPD has been discontinued[1][4][5][7].
- Other names
- danirixin
02
Targets
CXCR2 (C-X-C Motif Chemokine Receptor 2)
Beyond the preview
Go deeper on danirixin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on danirixin.